Intestinal Elimination of Ofloxacin Enantiomers in the Rat: Evidence of a Carrier-mediated Process

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1996 Sep 1

PMID 8878593

Citations 6

Authors

L Rabbaa

S Dautrey

N Colas-Linhart

C Carbon

R Farinotti

Affiliations

Soon will be listed here.

Abstract

The aim of this work was to examine the mechanism involved in intestinal elimination of the two optical isomers of ofloxacin in the rat. An intestinal segment was isolated in situ and perfused with saline, while drug solution was administered via the carotid artery. Blood samples and intestinal effluents were collected and analyzed by a high-performance liquid chromatography method. We observed saturable and stereoselective intestinal elimination of the ofloxacin enantiomers. The elimination process favored the R-(+) form of the molecule. After a parenteral dose of 20 mg of racemic ofloxacin per kg of body weight, intestinal clearances were 0.23 +/- 0.03 versus 0.30 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively. Ciprofloxacin and pefloxacin interfered with ofloxacin elimination and significantly reduced the intestinal clearance of S-(-)- and R-(+)-ofloxacin. With concomitant ciprofloxacin, intestinal clearances became 0.13 +/- 0.02 versus 0.17 +/- 0.03 ml/min and 0.14 +/- 0.01 versus 0.19 +/- 0.05 ml/min with pefloxacin for S-(-)- and R-(+)-ofloxacin, respectively. Those findings argue for the presence of a common transport system in the rat intestine with variable affinities for fluoroquinolones. In addition, verapamil and quinidine, two P-glycoprotein blockers, significantly reduced the intestinal elimination of both ofloxacin isomers (with concomitant verapamil, intestinal clearances were 0.12 +/- 0.02 versus 0.18 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively, while with concomitant quinidine, values were 0.18 +/- 0.01 versus 0.23 +/- 0.01 ml/min without modifying their areas under the concentration-time curve in serum. Similar results were found with another fluoroquinolone, ciprofloxacin, in previous work. P-glycoprotein appears to be involved in the intestinal elimination of fluoroquinolones in rats. The characterization of fluoroquinolone intestinal elimination has significant clinical relevance for the better evaluation of the influence of this secretory pathway on antibiotic efficacy and selection of resistant bacteria within the intestinal flora.

Citing Articles

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman E, Te Brake L, de Knegt G, van der Meijden A, Alffenaar J, Bax H Antimicrob Agents Chemother. 2018; 62(9).

PMID: 29987154 PMC: 6125510. DOI: 10.1128/AAC.01354-18.

Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

Schrickx J, Fink-Gremmels J Br J Pharmacol. 2007; 150(4):463-9.

PMID: 17211460 PMC: 2189727. DOI: 10.1038/sj.bjp.0706974.

Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.

Gokbulut C, Cirak V, Senlik B Vet Res Commun. 2006; 30(7):791-805.

PMID: 17004041 DOI: 10.1007/s11259-006-3336-y.

Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates.

Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R Br J Pharmacol. 1999; 127(7):1728-34.

PMID: 10455332 PMC: 1566149. DOI: 10.1038/sj.bjp.0702703.

Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils.

Vazifeh D, Bryskier A, Labro M Antimicrob Agents Chemother. 1999; 43(2):246-52.

PMID: 9925513 PMC: 89058. DOI: 10.1128/AAC.43.2.246.

References

Savina P, Staubus A, Gaginella T, Smith D . Optimal perfusion rate determined for in situ intestinal absorption studies in rats. J Pharm Sci. 1981; 70(3):239-43. DOI: 10.1002/jps.2600700303. View

SCHANKER L, TOCCO D, Brodie B, Hogben C . Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther. 1958; 123(1):81-8. View

Fass R . The quinolones. Ann Intern Med. 1985; 102(3):400-2. DOI: 10.7326/0003-4819-102-3-400. View

AFFOLTER H, Hertel C, Jaeggi K, Portenier M, STAEHELIN M . (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci U S A. 1985; 82(3):925-9. PMC: 397160. DOI: 10.1073/pnas.82.3.925. View

Weiland G, Oswald R . The mechanism of binding of dihydropyridine calcium channel blockers to rat brain membranes. J Biol Chem. 1985; 260(14):8456-64. View

Hirai K, Aoyama H, IRIKURA T, Iyobe S, Mitsuhashi S . Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother. 1986; 29(3):535-8. PMC: 180431. DOI: 10.1128/AAC.29.3.535. View

Hoiby N . Clinical uses of nalidixic acid analogues: the fluoroquinolones. Eur J Clin Microbiol. 1986; 5(2):138-40. DOI: 10.1007/BF02013968. View

Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham M . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987; 84(21):7735-8. PMC: 299375. DOI: 10.1073/pnas.84.21.7735. View

Lode H, Hoffken G, Olschewski P, Sievers B, KIRCH A, Borner K . Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987; 31(9):1338-42. PMC: 174938. DOI: 10.1128/AAC.31.9.1338. View

10.

Gasic S, Eichler H, Korn A . Comparative effects of verapamil, tiapamil, diltiazem and nifedipine on systemic and splanchnic hemodynamics in man. Int J Clin Pharmacol Ther Toxicol. 1987; 25(9):498-503. View

11.

Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P . Comparative pharmacokinetics of new quinolones. Drugs. 1987; 34 Suppl 1:21-5. DOI: 10.2165/00003495-198700341-00006. View

12.

Le Coguic A, Bidault R, Farinotti R, Dauphin A . Determination of ofloxacin in plasma and urine by liquid chromatography. J Chromatogr. 1988; 434(1):320-3. DOI: 10.1016/0378-4347(88)80095-1. View

13.

Croop J, Raymond M, Haber D, DeVault A, Arceci R, Gros P . The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989; 9(3):1346-50. PMC: 362730. DOI: 10.1128/mcb.9.3.1346-1350.1989. View

14.

Okazaki O, Kurata T, Tachizawa H . Stereoselective metabolic disposition of enantiomers of ofloxacin in rats. Xenobiotica. 1989; 19(4):419-29. DOI: 10.3109/00498258909042283. View

15.

Sorgel F, Naber K, Jaehde U, Reiter A, Seelmann R, Sigl G . Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med. 1989; 87(5A):62S-65S. DOI: 10.1016/0002-9343(89)90025-9. View

16.

Ford J, Hait W . Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990; 42(3):155-99. View

17.

Allen C, Harpur E, Gray T, Simmons N, Hirst B . Efflux of bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-dependent transport mechanism in epithelial cells. Biochem Biophys Res Commun. 1990; 172(1):262-7. DOI: 10.1016/s0006-291x(05)80203-7. View

18.

Fujimoto T, Mitsuhashi S . In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy. 1990; 36(4):268-76. DOI: 10.1159/000238777. View

19.

Ince P, Elliott K, Appleton D, Moorghen M, Finney K, Sunter J . Modulation by verapamil of vincristine pharmacokinetics and sensitivity to metaphase arrest of the normal rat colon in organ culture. Biochem Pharmacol. 1991; 41(8):1217-25. DOI: 10.1016/0006-2952(91)90661-n. View

20.

Puro V, Narciso P, Girardi E, Antonelli L, Zaccarelli M, Visco G . Male-to-female transmission of human immunodeficiency virus infection by oro-genital sex. Eur J Clin Microbiol Infect Dis. 1991; 10(1):47. DOI: 10.1007/BF01967102. View